LivaNova (LIVN) is back on investor radar after recent share moves, with the price near $77.16 and year-to-date total return around 27%, inviting closer attention to fundamentals.
LivaNova’s recent share price softness, with the 1 month share price return down 1.41% and 3 month share price return down 4.80%, comes against a stronger backdrop. This is highlighted by a 27.24% year to date share price gain and 44.96% 1 year total shareholder return, which signals momentum has built over the past year even as shorter term sentiment has cooled slightly.
Scan how LivaNova’s recent run compares with other potential breakouts by reviewing a curated set of 30 high quality undervalued stocks.
The recent pullback, set against LivaNova’s strong 1 year and 3 year track record, begs a simple question: Is the price now tracking business progress or a cooler mood among shareholders, and what does that mean for valuation?
Most Popular Narrative: 13% Undervalued
Against LivaNova's last close of $77.16, the most followed narrative points to a fair value of $89.10. This frames the recent pullback as a potential valuation gap rather than a change in the underlying story.
The company's clinical innovations including strong, durable VNS study data in epilepsy and depression, launch of disruptive next-generation OSA neurostimulation (p-HGNS), and continued product upgrades (such as the Essenz platform's software upgradability) position LivaNova to capture share from the long-term shift toward minimally invasive, personalized therapies, which can support pricing power and higher net margins.
See why 5 investors see LivaNova as 13% undervalued.
Result: Fair Value of $89.10 (UNDERVALUED)
Still, if healthcare cost controls tighten or regulators slow device approvals, the upbeat LivaNova narrative could meet resistance faster than bullish forecasts imply.
Find out about the key risks to this LivaNova narrative.
Next Steps
If that mix of optimism and concern around LivaNova leaves you on the fence, consider moving quickly, reviewing both sides of the story, and weighing the 4 key rewards and 2 important warning signs.
Looking for more LivaNova investment ideas?
If LivaNova has sharpened your attention, do not stop here. Broader ideas from the Simply Wall St Screener could reveal opportunities you will wish you checked earlier.
- Target stability first by reviewing a 31 resilient stocks with low risk scores that prioritizes resilience when markets turn choppy.
- Spot potential value candidates by scanning a focused 30 high quality undervalued stocks that combines quality fundamentals with discounted prices.
- Hunt for tomorrow's potential standouts by checking a 16 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com